Sarepta Therapeutics Q1 2024 Adj EPS $0.73 Beats $(0.07) Estimate, Sales $413.464M Beat $373.283M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 2024 earnings of $0.73 per share, surpassing the $(0.07) estimate, marking a 1142.86% beat and a 173.74% increase from last year's $(0.99) per share loss. Sales reached $413.464M, exceeding the $373.283M estimate by 10.76% and showing a 63.10% increase from last year's $253.500M.
May 01, 2024 | 8:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sarepta Therapeutics reported a significant beat on both earnings and sales for Q1 2024, with EPS at $0.73 against a $(0.07) estimate and sales of $413.464M against a $373.283M estimate.
The substantial beat on both earnings per share and sales estimates for Q1 2024 indicates a strong financial performance and operational efficiency, likely leading to positive investor sentiment and potential stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100